Besides, Patients with AML in the high-risk group generally contain higher proportions of IGF2BP3, ALKBH5, IGF2BP2, YTHDF3, YTHDC2, CBLL1, HNRNPA2B1 (Figure 6A). This evidence concerns the gene IGF2BP2 and acute myeloid leukemia.